SHAREHOLDER ALERT: Investigation of Ocugen Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) complied with federal securities laws. On January 12, 2021, Ocugen announced the cancellation of a Company stockholder meeting for the following day and plans to re-evaluate the details of a proposed increase in the number of shares of common stock "in light of the recent potential addition of COVAXIN™ to its pipeline as well as its...
2021-01-25 3:04 PM EST
SHAREHOLDER ALERT: Investigation of Eos Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Eos Energy Enterprises, Inc. ("Eos" or the "Company") (NASDAQ: EOSE) complied with federal securities laws. On January 14, 2021, analyst Iceberg Research published a report entitled "Eos Energy ($EOSE): Fake Customers Won't Recharge a Dead Battery" asserting that Eos is a battery energy storage systems special purpose acquisition company with "failed technology and dubious customers." The...
2021-01-25 2:53 PM EST
SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of Voyager Therapeutics Investors and Encourages Investors With Significant Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) securities between June 1, 2017 and November 9, 2020, inclusive (the "Class Period").The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's VY-HTT01 IND submission...
2021-01-25 2:51 PM EST
SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal securities laws. On January 8, 2021, Neoleukin announced that "on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate,...
2021-01-25 2:49 PM EST
SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of Lizhi Investors and Encourages Investors With Significant Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - January 21, 2021) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Lizhi, Inc. (NASDAQ: LIZI) ("Lizhi" or the "Company") securities traceable to the Company's January 17, 2020 initial public offering (the "IPO").The complaint alleges defendants made false and/or misleading statements and/or failed to disclose that: (1) at the time of the IPO, the coronavirus was already spreading in China, the...
2021-01-21 9:40 AM EST
SHAREHOLDER ALERT: Investigation of bluebird Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal securities laws. On November 4, 2020, the Company announced its submission to the FDA for approval of its bb1111 product will be delayed until late 2022. The price of bluebird's stock fell following the announcement. If you purchased shares of bluebird and suffered a loss on that investment, you are...
2020-11-11 10:04 AM EST
SHAREHOLDER ALERT: Investigation of Biogen Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether Biogen Inc. (NASDAQ: BIIB) ("Biogen" or the "Company") complied with federal securities laws. Trading in Biogen was halted on November 6, 2020, in advance of the Company's meeting with the FDA. On the same day, Bloomberg reported in an article titled "Biogen Alzheimer's Drug Fails to Gain FDA Panel's Backing," that "the outside experts voted 8 to 1, with 2 undecided, that...
2020-11-11 10:01 AM EST
SHAREHOLDER ALERT: Investigation of Columbia Sportswear Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - November 4, 2020) - Holzer & Holzer, LLC is investigating whether Columbia Sportswear Company (NASDAQ: COLM) ("Columbia Sportswear" or the "Company") complied with federal securities laws. On October 29, 2020, the Company announced its third quarter 2020 financial results and disclosed a 23% decline in net sales partly due to "approximately $45 million of Fall 2020 shipments shifting into fourth quarter 2020." The price of Columbia Sportswear's stock fell...
2020-11-04 3:40 PM EST
SHAREHOLDER ALERT: Investigation of Neovasc Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - November 3, 2020) - Holzer & Holzer, LLC is investigating whether Neovasc Inc. (NASDAQ: NVCN) ("Neovasc" or the "Company") complied with federal securities laws. On October 28, 2020, the Company announced that the FDA voted on its Neovasc Reducer and found against issuing a reasonable assurance of effectiveness and against whether the benefits outweigh the relative risks. The price of Neovasc's stock fell following the announcement. If you purchased shares...
2020-11-03 9:36 AM EST
SHAREHOLDER ALERT: Investigation of SAP Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - November 3, 2020) - Holzer & Holzer, LLC is investigating whether SAP SE (NYSE: SAP) ("SAP" or the "Company") complied with federal securities laws. On October 25, 2020, the Company announced it's third quarter 2020 financial results and lowered its full year 2020 outlook. The price of SAP's stock fell following the announcement. If you purchased shares of SAP and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer,...
2020-11-03 9:33 AM EST
SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of Celsion Investors and Encourages Investors With Significant Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - November 2, 2020) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company") securities between November 2, 2015 and July 10, 2020 (the "Class Period"). The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose: (1) defendants had significantly overstated the efficacy of...
2020-11-02 12:31 PM EST
SHAREHOLDER ALERT: Investigation of Intercept Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - November 2, 2020) - Holzer & Holzer, LLC is investigating whether Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) ("Intercept" or the "Company") complied with federal securities laws. In its most recent 10-Q filed with the SEC, the Company disclosed "the FDA has notified us that in the course of its routine safety surveillance, in May 2020 the FDA began to evaluate a newly identified safety signal regarding liver disorder for Ocaliva which the FDA classified...
2020-11-02 8:00 AM EST
SHAREHOLDER ALERT: Investigation of Innate Pharma Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - October 22, 2020) - Holzer & Holzer, LLC is investigating whether Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA) complied with federal securities laws. On September 8, 2020, the Company announced it had agreed to amend a previously negotiated agreement with AstraZeneca. The price of Innate's stock fell following the announcement. If you purchased shares of Innate and suffered a loss on that investment, you are encouraged to contact Corey D....
2020-10-22 1:41 PM EDT
SHAREHOLDER ALERT: Investigation of Myovant Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - September 29, 2020) - Holzer & Holzer, LLC is investigating whether Myovant Sciences Ltd. (NYSE: MYOV) ("Myovant" or the "Company") complied with federal securities laws. On September 29, 2020, the Company announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. The price of Myovant's stock fell following the announcement. If you purchased shares of Myovant and suffered a...
2020-09-29 10:30 AM EDT
SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of Golar Investors and Encourages Investors With Significant Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - September 25, 2020) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Golar LNG Limited (NASDAQ: GLNG) ("Golar" or the "Company") securities between April 24, 2020 and September 24, 2020 (the "Class Period"). The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose: (1) that certain employees, including Hygo's CEO, had bribed...
2020-09-25 9:49 AM EDT
SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of Wrap Investors and Encourages Investors With Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - September 24, 2020) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Wrap Technologies, Inc. ("Wrap" or the "Company") (NASDAQ: WRTC) securities between July 31, 2020 and September 23, 2020 (the "Class Period"). The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had concealed the results of the...
2020-09-24 11:22 AM EDT